Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 241 Cr.
- Current Price ₹ 241
- High / Low ₹ 448 / 198
- Stock P/E
- Book Value ₹ 194
- Dividend Yield 0.00 %
- ROCE -0.90 %
- ROE -1.12 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 1.98% over past five years.
- Company has a low return on equity of -3.23% over last 3 years.
- Earnings include an other income of Rs.9.21 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -5.67%
- Working capital days have increased from 255 days to 434 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|
62 | 99 | 213 | 256 | 111 | 92 | 110 | 124 | |
53 | 90 | 152 | 200 | 126 | 102 | 117 | 129 | |
Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | -6 |
OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | -5% |
0 | 0 | 3 | 8 | 7 | 11 | 12 | 9 | |
Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
Profit before tax | 9 | 9 | 62 | 61 | -11 | -3 | 1 | -0 |
Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | |
6 | 6 | 46 | 45 | -8 | -2 | 1 | 0 | |
EPS in Rs | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 0.00 |
Dividend Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 2% |
3 Years: | -25% |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -100% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -38% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | -3% |
Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 |
Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 |
0 | 10 | 4 | 4 | 3 | 3 | 5 | |
15 | 9 | 19 | 12 | 8 | 10 | 11 | |
Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 |
1 | 1 | 4 | 10 | 9 | 7 | 9 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 |
23 | 33 | 182 | 175 | 139 | 104 | 200 | |
Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
0 | -8 | 35 | 1 | 10 | -3 | -19 | |
-0 | -0 | -110 | -3 | -16 | 18 | 8 | |
-0 | 8 | 92 | -7 | -2 | -1 | -0 | |
Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 52 | 47 | 0 | 4 | 14 | 6 | 11 |
Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 |
Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 |
Cash Conversion Cycle | 87 | 107 | 103 | 165 | 157 | 161 | 190 |
Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 434 |
ROCE % | 57% | 67% | 33% | -6% | -4% | -1% |
Documents
Announcements
-
Filing Of Scheme Under Regulation 37(6) Of The SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations')
24 Jul - Filed draft scheme for merger of wholly owned subsidiary Nureca Technologies into Nureca Limited.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Jul
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
15 Jul - Nureca reports 70% YoY revenue growth to ₹34.18 Cr in Q1 FY26, highest in 10 quarters.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
15 Jul - Nureca Limited has informed regarding Investor Presentation
-
Board Meeting Outcome for Nureca Limited Has informed Regarding Unaudited Financial Results For The Quarter Ended 30Th June,2025.
15 Jul - Nureca reports Q1 FY26 unaudited standalone and consolidated financial results with auditor's unmodified review.
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26